This notice from Pfizer came by my desk today. Gentamycin, a drug used for gram-negative sepsis including Urospesis will be unavailable for 12 months. I'm seeing a great opportunity for some fast trial trials of Recce 327 based on treatment supply problems. We would only need one or two patients to be treated under a life or death situation to see a major increase to the SP. It could happen any day from May 2020.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.020(6.45%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $161.7K | 556.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10451 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 12600 | 1 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |